Double-blind crossoer clinical trial of pyridinolcarbamate in peripheral arterial disease (arteriosclerosis obliterans).
D001162:Arteriosclerosis Obliterans / Q000188:drug therapy* / Q000503:physiopathology; D001772:Blood Cell Count; D001920:Bradykinin / Q000037:antagonists & inhibitors; D002219:Carbamates / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006949:Hyperlipidemias / Q000503:physiopathology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D010991:Plethysmography; D011727:Pyridinolcarbamate / Q000627:therapeutic use; D012907:Smoking / Q000503:physiopathology; D014508:Urea / Q000097:blood; D014527:Uric Acid / Q000097:blood
D002219:Carbamates; D006454:Hemoglobins; D000960:Hypolipidemic Agents; D014527:Uric Acid; D011727:Pyridinolcarbamate; D014508:Urea; D002784:Cholesterol; D001920:Bradykinin